

In the Specification:

In the paragraph bridging pages 1 and 2, starting at page 1, line 11 to page 2, line 9, please insert the following paragraph:

The CXC chemokines that possess the receptor-signaling glutamic acid-~~lysine~~leucine-arginine (ELR) motif (e.g., CXCL1/GRO α , CXCL8/IL-8; ~~Baggiolini, M. 1998. Nature. 392:565-568~~ref. 1) are important to the influx of inflammatory cells that mediates much of the pathology in multiple settings, including ischemia-reperfusion injury (~~Sekido, N. et al. 1993. Nature. 365:654-657; Villard, J. et al. 1995. Am. J. Respir. Crit. Care Med. 152:1549-1554~~ref. 2, 3), endotoxemia-induced acute respiratory distress syndrome (ARDS; ~~Mukaida, N. et al. 1998. Inflamm. Res. 47 suppl. 3: S161-157~~ref. 4), arthritis, and immune complex-type glomerulonephritis (~~Harada, A. et al. 1996. Inflamm. Res. 2:482-489~~ref. 5). For instance, inappropriately released hydrolytic enzymes and reactive oxygen species from activated neutrophils initiate and/or perpetuate the pathologic processes. On the other hand, during most bacterial infections this chemokine response represents a critical first line of defense, but even here ELR⁺ CXC chemokine responses can, via their abilities to activate inflammatory cells displaying the CXCR1 and CXCR2 receptors, exacerbate the pathology. For example, during experimental 'cecal puncture and ligation' sepsis, neutralization of MIP-2 reduces mouse mortality from 85 to 38% (~~Walley, K. R. et al. 1997. Infect. Immun. 65:3847-3851~~ref. 6). And experimental treatments that eliminate circulating neutrophils ameliorate the pathology of pneumonic manheimiosis (~~Slocumbe, R. et al. 1985. Am. J. Vet. Res. 46:2253~~ref. 7), wherein CXCL8 expression in the airways variably effects the neutrophil chemoattraction~~[[.]]~~ ~~Gaswell, J. L. et al. 1997. Vet. Pathol. 35:124-134; Gaswell, J. L. et al. 2001. Canad. J. Vet. Res. 65:229-232~~ref. 8, 9). Despite the critical importance of these chemokine responses in many settings, wayward inflammatory cell responses are sufficiently

damaging that the development of therapeutic tools with which we can block ELR⁺ chemokines has become a research priority (~~Baggiolini, M., and B. Moser, 1997, J. Exp. Med. 186:1189-1194ref. 10).~~

In the paragraph bridging pages 2 and 3, starting at page 2, line 10 to page 3, line 5, please insert the following paragraph:

The 'ELR' chemokines chemoattract and activate inflammatory cells via their CXCR1 and CXCR2 receptors (~~Baggiolini, 1998; Ahuja, S. K., and P. M. Murphy, 1996, J. Biol. Chem. 271:20545-20550ref. 1, 11).~~ The CXCR1 is specific for CXCL8 and CXCL6/granulocyte chemotactic protein-2 (GCP-2), while the CXCR2 binds CXCL8 with high affinity, but also macrophage inflammatory protein-2 (MIP-2), CXCL1, CXCL5/ENA-78, and CXCL6 with somewhat lower affinities (see, for example, ~~Baggiolini and Moser, 1997ref. 10).~~ CXCL8 signaling in cell lines transfected with the human CXCR1 or CXCR2 induces equipotent chemotactic responses (~~Wuyts, A. et al. 1998, Eur. J. Biochem. 255:67-73; Richardson, R. et al. 1998, J. Biol. Chem. 273:23830-23836ref. 13, 14).~~ and while neutrophil cytosolic free Ca⁺⁺ changes and cellular degranulation in response to CXCL8 are also mediated by both receptors, the respiratory burst and activation of phospholipase D reportedly depend exclusively on the CXCR1 (~~Jones, S. A. et al. 1996, Proc. Natl. Acad. Sci. U.S.A. 93:6682-6686ref. 16).~~ On the other hand, it has been reported that a non-peptide antagonist of the CXCR2, but not the CXCR1, antagonizes CXCL8-mediated neutrophil chemotaxis, but not cellular activation (~~White, J. R. et al. 1998, J. Biol. Chem. 273:10095-10098ref. 17).~~ Finally, there is abundant evidence that chemokines are most often redundantly expressed during inflammatory responses (see, for example, ~~Caswell et al., 1997ref. 8).~~ But, despite active research in the field, no CXC chemokine antagonists are known in the prior art that are effective in suppressing adverse inflammatory cell activity induced by either ELR-CXC chemokine receptor.

In the paragraph at page 5, lines 2 to 17, please insert the following paragraph:

FIG. 1. The G31 P analogue of CXCL8₍₃₋₇₄₎K11R is a potent inhibitor of CXCL8-binding to peripheral blood neutrophils. Bovine peripheral blood neutrophils (87-93%purity) were (upper panel) exposed at 4°C for 2 h to CXCL8₍₃₋₇₄₎K11R analogues (10 ng/ml) or medium (med) alone, then washed and similarly incubated with biotinylated CXCL8 (^{biot}CXCL8; 1000 ng/ml or 129 nM). These levels of CXCL8 approximate those found in the lung tissues of animals with pneumonic pasteurellosis (ref. 8, 9). The levels of ^{biot}CXCL8 binding to the cells were determined using ELISA technology. The depicted amino acid substitutions within CXCL8₍₃₋₇₄₎K11R included: G31P; P32G; T12S/H13P/G31P; and T12S/H13P/G31P/P32G. The G31P, but not the P32G, analogue was a highly effective antagonist of CXCL8 binding to the cells. With both the G31P and P32G analogues, additional substitutions of T12S and H13F reduced their CXCL8 antagonist activities (lower panel). Neutrophils were exposed simultaneously for 45 min at 4.degree. C. to varying concentrations of CXCL8₍₃₋₇₄₎K11R/G31P or unlabeled CXCL8 and 20 pM ¹²⁵I-CXCL8. This level of ¹²⁵I-CXCL8 was chosen as nearly saturating for the cell's high affinity CXCL8 receptors (data not shown). The levels of cell-associated ¹²⁵I-CXCL8 were assessed using a counter. The data clearly indicate that CXCL8₍₃₋₇₄₎K11R/G31P had a substantially higher affinity for the neutrophils than CXCL8.

In the paragraph bridging pages 5 and 6, starting at page 5, line 18 to page 6, line 10, please insert the following paragraph:

FIG. 2. CXCL8₍₃₋₇₄₎K11R/G31P is not an agonist of neutrophil chemoattraction responses or β -glucuronidase release. CXCL8 and the G31P, P32G, or combined G31P/P32G analogues of CXCL8₍₃₋₇₄₎K11R were tested for their neutrophil agonist activities, using freshly purified bovine peripheral blood neutrophils.

(upper panel) The chemotactic responses to each protein were tested in 30 min microchemotaxis assays and the results expressed as the mean (\pm SEM) number of cells/40x objective microscope field, as outlined in the methods section. Both the G31P and G31P/P32G analogues displayed little ~~discernable~~discernable chemotactic activity, while the P32G analogue stimulated substantial responses at 100 ng/ml. (lower panel) The neutrophils were exposed to varying doses of each analogue for 30 min, then the cellular secretion products were assayed for β -glucuronidase using the chromogenic substrate p-nitrophenyl- β -D-glucuronide, as presented in the methods section. The total cellular stores of β -glucuronidase were determined from aliquots of cells lysed with Triton-X-100. The enzyme release with each treatment is expressed as the percent of the total cellular stores. None of the analogues had substantial agonist activity, although CXCL8 itself did induce significant enzyme release. The positive control treatment with phorbol-12,13-myristate acetate and calcium ionophore A23187 induced $42 \pm 6\%$ enzyme release.

In the paragraph at page 9, lines 10 to 23, please insert the following paragraph:

When amino terminal truncation of bovine CXCL8 is combined with a lysine to arginine substitution at amino acid 11 (i.e., CXCL8₍₃₋₇₄₎K11R), dramatic increases in CXCR1 and CXCR2 receptor affinity are evident, such that CXCL8₍₃₋₇₄₎K11R competitively inhibits the binding of multiple ligands to both receptors (Li, F., and J. R. Gordon. 2001. ~~Biochem. Biophys. Res. Comm. 286:595-600~~[[.]]ref. 24)[[.]] hereby incorporated by reference. Further truncation into the receptor-signaling ELR motif (e.g., amino acids 4-6 of human CXCL8) of some CXC chemokines can transform them into mild (CXCL8₍₆₋₇₂₎) to moderate (CXCL1₍₆₋₇₃₎) receptor antagonists (McCell and Clark-Lewis 1999; Moser, B. et al. 1993. ~~J. Biol. Chem. 268:7125-7128~~ref. 15, 25). As disclosed herein, the introduction into bovine CXCL8₍₃₋₇₄₎K11R of

a second amino acid substitution, glycine 31 to a proline residue (i.e., CXCL8₍₃₋₇₄₎K11R/G31P), renders this CXCL8 analogue a very high affinity antagonist of bovine and human ELR-CXC chemokine responses. It fully antagonizes the entire array of ELR-CXC chemokines expressed within bacterial or endotoxin-induced inflammatory foci and blocks endotoxin-induced inflammation in vivo.

In the paragraph at page 10, lines 1 to 5, please insert the following paragraph:

Although the following discussion deals primarily with bovine neutrophils, other mammalian (including human) inflammatory cells also display CXCR1 and CXCR2 receptors (see, for example, ~~Benson, M. et al. 1999, *Pediatr. Allergy Immunol.* 10:178-185~~ref. 52) and so are vulnerable to inhibition by CXCL8₍₃₋₇₄₎K11R/G31P. Accordingly, the present invention has broad applicability to mammalian ELR-CXC chemokine-mediated pathologies.

In the paragraph at page 10, lines 6 to 12, please insert the following paragraph:

In an alternate embodiment of the invention, it is envisioned that compounds having the same three dimensional structure at the binding site may be used as antagonists. Three dimensional analysis of chemical structure is used to determine the structure of active sites, including binding sites for chemokines. Chemical leads with high throughput screening have been used to generate and chemically optimize a selective antagonist of the CXCR2 (~~J Biol Chem, 1998, 273:10095, herein incorporated by reference~~ref. 17). A similar approach was also used to generate a CCR3 antagonist (~~J Biol Chem, 2000, 275:36626, herein incorporated by reference~~ref. 56).

In the paragraph at page 10, lines 13 to 17, please insert the following paragraph:

Wells et al (~~J Leuk Biol, 1996, 59:53, herein incorporated by~~
~~reference ref. 57~~), has employed nuclear magnetic resonance spectroscopy (NMR) to detail the three dimensional structure of ligands for CXCR, including both ELR and non-ELR CXC chemokines. With their NMR information, Wells et al generated multiple substitutions within the receptor binding sites of multiple chemokines, such that they could substantially alter the ligands' receptor specificities.

In the paragraph bridging pages 10 and 11, starting at page 10, line 18 to page 11, line 12, please insert the following paragraph:

Reagents & supplies. The following reagents were purchased commercially: glutathione-Sepharose, the expression vector pGEX-2T, Sephadex G-25 (Amersham-Pharmacia-Biotech, Baie d'Urf, PQ), Bolton-Hunter reagent, a protein biotinylation kit (Pierce Scientific, Rockford, Ill.), the sequencing vector pBluescript II KS, Pfu Turbo.TM. DNA polymerase (Stratagene, La Jolla, Calif.), a site-directed mutagenesis kit (QuickChange.TM.; Boehringer-Mannheim Canada, Laval, PQ), aprotinin, benzene, calcium ionophore A23187, chloramine T, cytochalasin B, dimethylformamide, endotoxin (Escherichia coli lipopolysaccharide, serotype 0127B8), isopropyl-thio-D-galactopyranoside (IPTG), leupeptin, p-nitrophenyl- β -D-glucuronide, mineral oil, silicon oil, tetramethylbenzidine (TMB), phenylmethylsulfonyl fluoride (PMSF), phorbol-12,13-myristate acetate (PMA), and Triton X-100 (Sigma Chemical Co, Mississauga, ON), a Diff-Quick staining kit (American Scientific Products, McGaw Pk, Ill.), human CXCL1, CXCL5, and CXCL8 (R & D Systems Inc, Minneapolis, Minn.), horse radish peroxidase (HRP)-conjugated anti-rabbit Ig (Zymed, South San Francisco, Calif.), DMEM, HBSS (Gibco, Grand Island, N.Y.), HRP-streptavidin (Vector Labs, Burlingame, Calif.), ABTS enzyme substrate (Kirkegaard & Perry Labs, Gaithersburg, Md.), bovine serum albumin (BSA), and Lymphocyte Separation Medium (ICN Pharmaceuticals, Aurora, Ill.).

In the paragraph bridging pages 11 and 12, starting at page 11, line 14 to page 12, line 9, please insert the following paragraph:

Generation of CXCL8₍₃₋₇₄₎K11R analogues. The high affinity CXCR1/CXCR2 ligand CXCL8₍₃₋₇₄₎K11R, and its T12S/H13F analogue were generated in accordance with the methods described in Li and Gordon (2004, ~~supra~~ref. 24). The Gly31Pro (G31P), Pro32Gly (P32G), and G31P/P32G analogues of these proteins were similarly generated by site-directed mutagenesis using PCR with the appropriate forward and reverse oligonucleotide primers (Table 1). The products from each reaction were digested with DpnI, ligated into the vector pGEX-2T, transfected into HB101 cells, and their sequences verified commercially (Plant Biotechnology Institute, Saskatoon). Briefly, the recombinant bacteria were lysed in the presence of a protease inhibitor cocktail (2 mM PMSF, 2 µg/ml aprotinin, and 2 µg/ml leupeptin) and the recombinant fusion proteins in the supernatants purified by affinity chromatography, using glutathione-Sepharose beads in accordance with the methods of Caswell et al. (~~Caswell, J. L., D. M. Middleton, and J. R. Gordon. 1998. Vet. Immunol. Immunopath. 67:327-340.ref. 26).~~ The CXCL8₍₃₋₇₄₎K11R analogues were cleaved from the GST fusion proteins by thrombin digestion, dialysed against phosphate buffered saline (PBS), run through commercial endotoxin-removal columns, and then characterized by polyacrylamide gel electrophoresis (PAGE) and Western blotting with a goat anti-bovine CXCL8 antibody (provided by Dr. M. Morsey). Each purified analogue had a molecular mass of 8 kDa, was specifically recognized by the anti-CXCL8 antibody in the Western blotting, and had a relative purity of 96%, as determined by densitometric analysis of the PAGE gels.

In the paragraph at page 12, lines 11 to 19, please insert the following paragraph:

Labeling of the recombinant proteins. We used ^{biot}CXCL8 for the initial surveys of analogue binding to neutrophils and ¹²⁵I-CXCL8 for the later stage assays of relative receptor affinity. CXCL8 was biotinylated and the levels of biotin substitution determined using a commercial kit, as noted in Li and Gordon (2004, ~~supreref. 24~~). The ^{biot}CXCL8 was substituted with 2.15 moles of biotin per mole of CXCL8. CXCL8 was radiolabeled with ¹²⁵I using the Bolton-Hunter Reagent (BHR) method, as noted in detail (Li and Gordon 2001, ~~supreref. 24~~). The labeled protein was separated from the unincorporated ¹²⁵I-BHR by chromatography on Sephadex G50, and the labeled CXCL8 characterized for its relative affinity for neutrophils and the time required to achieve binding equilibrium, as noted in Li and Gordon (2004, ~~supreref. 24~~).

In the paragraph bridging pages 12 and 13, starting at page 12, line 21 to page 13, line 8, please insert the following paragraph:

CXCL8₍₃₋₇₄₎K11R analogue binding assays. Cells (85-93% neutrophils) were purified from the blood of cattle in accordance with the Caswell method (Caswell, J. L. et al. 1998. ~~Vet. Immunol. Immunopath. 67:327-340ref. 26~~). In preliminary experiments, we determined that none of our analogues affected the viability of neutrophils, as determined by trypan blue dye exclusion. For the broad analogue surveys, neutrophils in HBSS/0.5% BSA were incubated for 2 h at 4°C. with the analogue, washed in cold DMEM, and then incubated for another 2 h at 4°C. with ^{biot}CXCL8 (1000 ng/ml). The cell-associated biotin was detected by incubating the washed cells with alkaline phosphatase-conjugated streptavidin (1:700 dilution) and then with ABTS enzyme substrate. The OD₄₀₅ of the samples was determined using an ELISA plate reader. Medium-treated neutrophils routinely bound sufficient ~~sup~~.biotCXCL8 to generate an OD₄₀₅ of 0.5-0.6.

In the paragraph at page 13, lines 9 to 19, please insert the following paragraph:

For the in-depth studies with CXCL8₍₃₋₇₄₎K11R/G31P, we used ¹²⁵I-CXCL8 in binding inhibition assays with unlabeled CXCL8 or CXCL8₍₃₋₇₄₎K11R/G31P. In preliminary experiments we determined that the binding equilibrium time of neutrophils for ¹²⁵I-CXCL8 was 45 min and that 20 pM ¹²⁵I-CXCL8 just saturated the cell's high affinity receptors. Thus, in our assays, 10⁶ purified neutrophils were incubated for 45 min on ice with 20 pM ¹²⁵I-CXCL8 and varying concentrations of unlabeled competitor ligand. The cells were then sedimented through 6% mineral oil in silicon oil and the levels of cell-associated radio-ligand determined using a counter. The non-specific binding of ¹²⁵I-CXCL8 to the cells was assessed in each assay by including a 200-fold molar excess of unlabeled ligand in a set of samples. This value was used to calculate the percent specific binding (Geligan, J., A. Kruisbeek, D. Margulies, E. Shevach, and W. Strober, 1994. Current Protocols in Immunology. John Wiley & Sons, New Yorkref. 27).

In the paragraph bridging pages 13 and 14, starting at page 13, line 21 to page 14, line 4, please insert the following paragraph:

Neutrophil β -glucuronidase release assay. The neutrophil β -glucuronidase assay has been reported in detail (Li and Gordon 2001, supreref. 24). Briefly, cytochalasin B-treated neutrophils were incubated for 30 min with the CXCL8 analogues, then their secretion products assayed calorimetrically for the enzyme. β -Glucuronidase release was expressed as the percent of the total cellular content, determined by lysing medium-treated cells with 0.2% (v/v) Triton X- 100. Neutrophil challenge with the positive control stimulus PMA (50 ng/ml) and A23187 (1 μ g/ml) induced 42 \pm 6% release of the total cellular β -glucuronidase stores.

In the paragraph at page 14, lines 6 to 17, please insert the following paragraph:

Samples from inflammatory lesions. We obtained bronchoalveolar lavage fluids (BALF) from the lungs of cattle (n=4) with diagnosed clinical fibrinopurulent pneumonic manheimiosis (~~Caswell et al., 1997~~ref. 8), as well as teat cistern wash fluids from cattle (n=4) with experimental endotoxin-induced mastitis (~~Waller, K. P. 1997. Vet. Immunol. Immunopathol. 57:239-254~~ref. 28). In preliminary dose-response experiments we determined that 5 µg of endotoxin induced a strong (70-80% maximal) mammary neutrophil response. Thus, in the reported experiments mastitis was induced by infusion of 5 µg of endotoxin or carrier medium alone (saline; 3 ml volumes) into the teat cisterns of nonlactating Holstein dairy cows, and 15 h later the infiltrates were recovered from the cisterns by lavage with 30 ml HBSS. The cells from the BALF and teat cistern wash fluids were sedimented by centrifugation and differential counts performed. Untreated and CXCL8-depleted (below) wash fluids were assessed for their chemokine content by ELISA (CXCL8 only) and chemotaxis assays.

In the paragraph bridging pages 14 and 15, starting at page 14, line 19 to page 15, line 12, please insert the following paragraph:

Neutrophil chemotaxis assays. Microchemotaxis assays were run in duplicate modified Boyden microchemotaxis chambers using polyvinylpyrrolidone-free 5 µm pore-size polycarbonate filters, in accordance with known methods (~~Caswell et al., 1998; Cairns, C. M. et al. 2001. J. Immunol. 167:67-65~~ref. 26, 29). For each sample, the numbers of cells that had migrated into the membranes over 20-30 min were enumerated by direct counting of at least nine 40x objective fields, and the results expressed as the mean number of cells/40x field (+/- SEM). The chemoattractants included bovine or human CXCL8, human CXCL5 and CXCL1,

pneumonic manheimiosis BALF and mastitis lavage fluids (diluted 1:10-1:80 in HBSS), while the antagonists comprised mouse anti-ovine CXCL8 antibody 8M6 (generously provided by Dr. P. Wood, CSIRO, Australia) or the CXCL8₍₃₋₇₄₎K11R analogues. In some assays we preincubated the samples with the antibodies (5 µg/ml) for 60 min on ice (~~Gordon, J. R. 2000. Cell Immunol. 201:42-49ref. 30~~). In others we generated CXCL8-specific immunoaffinity matrices with the 8M6 antibodies and protein-A-Sepharose beads and used these in excess to absorb the samples (~~Caswell et al. 1997; Gordon, J. R., and S. J. Galli. 1994. J. Exp. Med. 180:2027-2037ref. 8, 31~~); the extent of CXCL8 depletion was confirmed by ELISA of the treated samples. For assays with the recombinant antagonists, the inhibitors were mixed directly with the samples immediately prior to testing.

In the paragraph at page 15, lines 14 to 18, please insert the following paragraph:

CXCL8 ELISA. For our ELISA, MAb 8M6 was used as the capture antibody, rabbit anti-ovine CXCL8 antiserum (also from P. Wood, CSIRO) as the secondary antibody, and HRP conjugated anti-rabbit Ig, and TMB as the detection system, as noted in Caswell et al. (~~1997ref. 8~~). Serial dilutions of each sample were assayed in triplicate, and each assay included a recombinant bovine CXCL8 standard curve.

In the paragraph bridging pages 15 and 16, starting at page 15, line 20 to page 16, line 11, please insert the following paragraph:

CXCL8₍₃₋₇₄₎K11R/G31P blockade of endotoxin responses in vivo. We used a sequential series of 15 h skin tests to test the ability of CXCL8₍₃₋₇₄₎K11R/G31P to block endotoxin induced inflammatory responses in vivo. For each test, we challenged 2 week-old healthy Holstein cows intradermally with 1 µg endotoxin in 100 µl saline, then 15 h later took 6 mm punch biopsies under local anaesthesia

(lidocaine) and processed these for histopathology (~~Gordon and Galli, 1994~~ref. 31). Following the first (internal positive control) test, we injected each animal subcutaneously, intramuscularly, or intravenously with CXCL8₍₃₋₇₄₎K11R/G31P (75 µg/kg) in saline, then challenged them again with endotoxin, as above. The animals were challenged a total of 4 times with endotoxin, such that 15 h reaction site biopsies were obtained at 0, 16, 48, and 72 h post-treatment. The biopsies were processed by routine methods to 6 µm paraffin sections, stained with Giemsa solution, and examined in a blinded fashion at 400- magnification (~~Gordon and Galli, 1994; Gordon, J. R. 2000. J. Allergy Clin. Immunol. 106:110-116~~ref. 31, 32). The mean numbers of neutrophils per 40x objective microscope field were determined at three different depths within the skin, the papillary (superficial), intermediate, and reticular (deep) dermis.

In the paragraph at page 17, lines 2 to 17, please insert the following paragraph:

CXCL8₍₃₋₇₄₎K11R/G31P competitively inhibits CXCL8 binding to neutrophils. We surveyed the ability of each CXCL8₍₃₋₇₄₎K11R analogue to bind to the CXCL8 receptors on neutrophils, and thereby compete with CXCL8 as a ligand. In our initial surveys, we employed ^{biot}CXCL8 binding inhibition assays, incubating the cells with the analogues (10 ng/ml) for 2 h at 4°C. prior to exposure to ^{biot}CXCL8 (1 µg/ml). This level of CXCL8 approximates those found in the lung tissues of sheep with experimental pneumonic manheimiosis (~~Caswell, J. L. 1998. The role of interleukin-8 as a neutrophil chemoattractant in bovine bronchopneumonia. Ph.D. thesis, Department of Veterinary Pathology, University of Saskatchewan~~ref. 33). We found that CXCL8₍₃₋₇₄₎K11R/G31P was a potent antagonist of CXCL8 binding in this assay (FIG. 1), such that 10 ng/ml of CXCL8₍₃₋₇₄₎K11R/G31P blocked 95% of subsequent ^{biot}CXCL8 binding to the cells. When tested at this dose, CXCL8₍₃₋₇₄₎K11R/P32G

blocked only 48% of CXCL8 binding, while unlabeled CXCL8 itself competitively inhibited 30% of ^{biot}CXCL8 binding. Introduction into CXCL8₍₃₋₇₄₎K11R/G31P or CXCL8₍₃₋₇₄₎K11R/P32G of additional amino acid substitutions at Thr12 and His13 substantially reduced the antagonist activities of the analogues (FIG. 1). This data clearly suggests that pre-incubation of neutrophils with CXCL8₍₃₋₇₄₎K11R/G31P strongly down-regulates subsequent binding of CXCL8.

In the paragraph bridging pages 17 and 18, starting at page 17, line 18 to page 18, line 2, please insert the following paragraph:

In order to more finely map the ability of CXCL8₍₃₋₇₄₎K11R/G31P to inhibit the binding of CXCL8, in our next set of experiments we simultaneously exposed the cells to ¹²⁵I-CXCL8 and varying doses of CXCL8₍₃₋₇₄₎K11R/G31P or unlabeled CXCL8. We found that CXCL8₍₃₋₇₄₎K11R/G31P was about two orders of magnitude more effective than wildtype CXCL8 in inhibiting the binding of 20 pM ¹²⁵I-CXCL8 to the cells (FIG. 1). The concentration for inhibiting 50% of ~~labeled~~labelled ligand binding (IC₅₀) was 120 pM for unlabelled CXCL8, and 4 pM for CXCL8₍₃₋₇₄₎K11R/G31P. This data suggests that CXCL8₍₃₋₇₄₎K11R/G31P is a very potent competitive inhibitor of CXCL8 binding to neutrophils.

In the paragraph at page 18, lines 3 to 18, please insert the following paragraph:

CXCL8₍₃₋₇₄₎K11R/G31P does not display neutrophil agonist activities. While CXCL8₍₃₋₇₄₎K11R/G31P was certainly a high affinity ligand for the neutrophil CXCL8 receptors, it would equally well do so as an agonist or an antagonist. Thus our next experiments addressed the potential agonist activities of the CXCL8₍₃₋₇₄₎K11R analogues we generated, as measured by their abilities to chemoattract these cells or induce release of the neutrophil granule hydrolytic enzyme β -glucuronidase in vitro (FIG. 2). We found that even at 100 ng/ml, CXCL8₍₃₋₇₄₎K11R/G31P was a poor

chemoattractant, inducing 13.9+/-4% or 5.4+/-2% of the responses induced by 1 or 100 ng/ml CXCL8 ($p < 0.001$), respectively. At 100 ng/ml, the CXCL8₍₃₋₇₄₎K11R/P32G analogue induced a response that was fairly substantial (38.3+/-2% of the CXCL8 response), while the combined CXCL8₍₃₋₇₄₎K11R/G31P/P32G analogue also was not an effective chemoattractant. When we assessed their abilities to induce β -glucuronidase release, we found that none of the CXCL8₍₃₋₇₄₎K11R analogues was as effective as CXCL8 in inducing mediator release. Indeed, we found only background release with any of them at 10 ng/ml, and at 100 ng/ml only CXCL8₍₃₋₇₄₎K11R/G31P/P32G induced significant neutrophil responses (FIG. 2). Given the combined CXCL8 competitive inhibition and neutrophil agonist data, from this point on we focused our attention on CXCL8₍₃₋₇₄₎K11R/G31P.

In the paragraph bridging pages 18 and 19, starting at page 18, line 20 to page 19, line 6, please insert the following paragraph:

CXCL8₍₃₋₇₄₎K11R/G31P blocks neutrophil chemotactic responses to both CXCR1 and CXCR2 ligands. The most pathogenic effect of inappropriate ELR⁺ chemokine expression is the attraction of inflammatory cells into tissues. Thus, we next assessed the impact of CXCL8₍₃₋₇₄₎K11R/G31P on the chemotactic responses of neutrophils to high doses of CXCL8 (FIG. 3). As predicted from our in vivo observations in sheep and cattle (ref. 33), 1 μ g/ml (129 nM) CXCL8 was very strongly chemoattractive, but even very low doses of CXCL8₍₃₋₇₄₎K11R/G31P ameliorated this response. The addition of 12.9 pM CXCL8₍₃₋₇₄₎K11R/G31P reduced the chemotactic response of the cells by 33%. The IC₅₀ for CXCL8₍₃₋₇₄₎K11R/G31P under these conditions was 0.11 nM, while complete blocking of this CXCL8 response was achieved with 10 nM CXCL8₍₃₋₇₄₎K11R/G31P.

In the paragraph at page 19, lines 8 to 19, please insert the following paragraph:

When we tested the efficacy of CXCL8₍₃₋₇₄₎K11R/G31P in blocking responses to more subtle bovine CXCL8 challenges, we also extended the study to assess the ability of CXCL8₍₃₋₇₄₎K11R/G31P to block neutrophil responses to human CXCL8 as well as to the human CXCR2-specific ligands CXCL1 and CXCL5. Each of these is expressed in the affected tissues of pancreatitis (~~Hochreiter, W. W. et al. 2000. Urology. 56:1025-1029ref. 34~~) or ARDS (~~Villard et al., 1995ref. 3~~) patients at 1-10 ng/ml. We found that bovine neutrophils were responsive to 1 ng/ml hCXCL1 or hCXCL5, and similarly responsive to 10 ng/ml hCXCL8 (FIG. 3), so we employed these doses to test the effects of CXCL8₍₃₋₇₄₎K11R/G31P on neutrophil responses of these ligands. The neutrophil responses to hCXCL1 and hCXCL5 were reduced to 50% by 0.26 and 0.06 nM CXCL8₍₃₋₇₄₎K11R/G31P, respectively, while their responses to hCXCL8 were 50% reduced by 0.04 nM CXCL8₍₃₋₇₄₎K11R/G31P (FIG. 3). This data indicates that CXCL8₍₃₋₇₄₎K11R/G31P can antagonize the actions of multiple members of the ELR-CXC subfamily of chemokines.

In the paragraph bridging pages 19 and 20, starting at page 19, line 21 to page 20, line 17, please insert the following paragraph:

CXCL8₍₃₋₇₄₎K11R/G31P is an effective in vitro antagonist of the neutrophil chemokines expressed in bacterial pneumonia or mastitis lesions. We wished to test the extent to which our antagonist could block the array of neutrophil chemoattractants expressed within complex inflammatory environments in vivo. Thus, we chose two diseases in which chemokine-driven neutrophil activation contributes importantly to the progression of the pathology, mastitis and pneumonic manheimiosis. We utilized an endotoxin model of mastitis (~~Persson, K. et al., 1993. Vet. Immunol. Immunopathol. 37:99-112ref. 35~~), in which we infused 5 µg of endotoxin/teat cistern and 15 h later lavaged each cistern. Neutrophils comprised 82 and 6%, respectively, of the cells from endotoxin and saline-control cisterns, with the

bulk of the remaining cells comprising macrophages. The diluted (1:10) wash fluids induced strong in vitro neutrophil chemotactic responses, and the addition of anti-CXCL8 antibodies to the samples maximally reduced these by 73 \pm 8% (FIG. 4A), relative to the medium control. On the other hand, the addition of 1 ng/ml of CXCL8₍₃₋₇₄₎K11R/G31P to the samples reduced their chemotactic activity by 97 \pm 3%.

In the paragraph bridging pages 20 and 21, starting at page 20, line 18 to page 21, line 8, please insert the following paragraph:

In order to confirm these observations using an alternate strategy, we next depleted bacterial pneumonia BALF samples of CXCL8 using immunoaffinity matrices, then assessed the efficacy of CXCL8₍₃₋₇₄₎K11R/G31P in blocking the residual neutrophil chemotactic activities in the samples (FIG. 4B). The untreated lesional BALF samples contained 3,215 \pm 275 pg/ml CXCL8, while the immunoaffinity-absorbed BALF contained 24 \pm 17 pg/ml CXCL8. In this series of experiments the neutrophil response to the CXCL8-depleted BALF samples was 65.4 \pm 4% of their responses to the unabsorbed samples. It is known that CXCL8 can contribute as little as 15% of the neutrophil chemotactic activities in pneumonic mannheimiosis BALF obtained from an array of clinical cases (Caswell et al., 2004 ref. 9). Whereas the CXCL8 depletion treatments were 99% effective in removing CXCL8, there remained in these samples substantial amounts of neutrophil chemotactic activities, and the addition of 1 ng/ml CXCL8₍₃₋₇₄₎K11R/G31P fully abrogated their cumulative effects (FIG. 4B). This data unequivocally confirmed that CXCL8₍₃₋₇₄₎K11R/G31P also antagonizes the spectrum of non-IL-8 chemoattractants expressed in these samples.

In the paragraph at page 23, lines 1 to 4, please insert the following paragraph:

This data clearly indicates that bovine G31P is an effective antagonist of the bovine ELR-CXC chemokines expressed in vivo in response to endotoxin challenge, but also can fully antagonize neutrophil and eosinophil ELR-CXC chemokine receptor responses to CXCL8 and CXCL5, known ligands for both the CXCR1 and CXCR2.

In the paragraph bridging pages 24 and 25, starting at page 24, line 22 to page 25, line 9, please insert the following paragraph:

We demonstrated herein that CXCL8₍₃₋₇₄₎K11R/G31P is a high affinity antagonist of multiple ELR-CXC chemokines. In vitro, this antagonist effectively blocked all of the neutrophil chemotactic activities expressed in mild to intense inflammatory lesions within two mucosal compartments (lungs, mammary glands), and up to 97% blocked endotoxin-induced inflammatory responses in vivo. We identified CXCL8 as a major chemoattractant in the pneumonia and mastitis samples, but also demonstrated that 35% of the activity in the bacterial pneumonia samples was due to non-CXCL8 chemoattractants that were also effectively antagonized by CXCL8₍₃₋₇₄₎K11R/G31P. Based on studies of inflammatory responses in rodents (Tateda et al., 2001; Tsai et al., 2000 ref. 18, 19), cattle (Gaswell et al., 1997 ref. 8), and humans (Villard et al., 1995 ref. 3), it is clear that these samples could contain numerous ELR⁺ CXC chemokines (e.g., CXCL5, and CXCL8) to which CXCL8₍₃₋₇₄₎K11R/G31P has an antagonistic effect.

At page 33, line 6, please insert the following following two new paragraphs:

56. White JR, Lee JM, Dede K, Imburgia CS, Jurewicz AJ, Chan G, Fornwald JA, Dhanak D, Christmann LT, Darcy MG, Widdowson KL, Foley JJ, Schmidt DB, Sarau HM. 2000. Identification of potent, selective non-peptide CC

chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2-, and monocyte chemotactic protein-4-induced eosinophil migration. *J Biol Chem.* 275(47):36626-31.

57. Wells TN, Power CA, Lusti-Narasimhan M, Hoogewerf AJ, Cooke RM, Chung CW, Peitsch MC, Proudfoot AE. 1996. Selectivity and antagonism of chemokine receptors. *J Leukoc Biol.* 59(1):53-60.